Risk Estimation for Leukemogenic Drugs

  • J. M. Kaldor
  • D. E. G. Shuker


A number of drugs used in cancer chemotherapy are known to be highly leukemogenic. Because the cancer risks per unit dose can be estimated more precisely for these drugs than for many other human carcinogens, they provide a unique opportunity to test the predictions of cancer risk models, and bioassay outcomes. The available data on leukemia incidence following cytostatic drug treatment are reviewed, with regard to differences in potency. Quantitative data from animal bioassays are also used as the basis for potency estimates, and the correlation with the human data is examined. Chemical and biochemical properties of several of the drugs are then discussed, with view to explaining some of the observed differences in leukemogenic potency.


Polycythemia Vera Carcinogenic Risk Cytostatic Drug Nitrogen Mustard Human Carcinogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. BEIR, 1980, “The Effects on Populations of Exposure to Low Levels of Ionizing Radiation”, Committee on the Biological Effects of Ionizing Radiation (BEIR I II ), National Academy of Sciences, Washington, D.C.Google Scholar
  2. Berk, P. D., Goldberg, J. D., Silverstein, M. N., Weinfeld, A., Donovan, P. B., Ellis, J. T., Landaw, S. A., Laszlo, J., Najean, Y., Pisciotta, A. V., and Wasserman, L. R., 1981, Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. New Engl. J. Med.. 304: 441.PubMedCrossRefGoogle Scholar
  3. Boice, J. D., Greene, M. H., Killen, J. Y., Ellenberg, S. S., Keehn, R. J., McFadden, E., Chen, T., and Fraumeni, J. F., 1983, Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). New Engl. J. Med., 309: 1079.PubMedCrossRefGoogle Scholar
  4. Connors, T. A., 1987, Antitumor alkylating agents: cytotoxic actin and organ toxicity, in: Carcinogenicity of alkylating cytostatic drugs, (IARC Scientific Publications No 78), D. Schmähl, and J. M. Kaldor, eds., International Agency for Research on Cancer, Lyon.Google Scholar
  5. Doll, R., 1971, The age distribution of cancer: implications for models of carcinogenesis (with Discussion), J. Roy. Stat. Soc., 134: 133.CrossRefGoogle Scholar
  6. Fisher, B., Rockette, H., Fisher, E. R., Wickerham, L., Redmond, C., and Brown, A., 1985, Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSAPB experience. J. clin. Oncol., 3: 1640.PubMedGoogle Scholar
  7. Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de Veciana, M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., Peto, R., Pike, M.C., and Ames, B. N., 1984, A carcinogenic potency database of the standardized results of animal bioassay. Environ Health Perspect., 58: 9.PubMedCrossRefGoogle Scholar
  8. Greene, M. H., Boice, J. D., Greer, B. E., Blessin, J. A., and Dembo, A. J., 1982, Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer - a study of five randomized trials. New Engl. J. Med., 307: 1416.PubMedCrossRefGoogle Scholar
  9. Greene, M. H., Harris, E. L., Gershenson, D. M., Malkasian, G. D., Melton, L. J., Dembo, A. J., Bennett, J. M., Moloney, W. R., and Boice, J. D., 1986, Melphalan may be a more potent leukemogen than is cyclophosphamide. Ann. intern. Med., 105: 360.PubMedCrossRefGoogle Scholar
  10. Hemminki, K., Kallama, S., and Falck, K., 1983, Correlations of alkylating activity and mutagenicity in bacteria of cytostatic drugs, Acta Pharmacol. Toxicol., 53: 421.Google Scholar
  11. Hemminki, K., and Kallama, S., 1986, Reactions on nitrogen mustards with DNA, in: “Carcinogenicty of Alkylating Cytostatic Drugs (IARC Scientific Publications No 78)”, D. Schmähl, and J. M. Kaldor, eds, International Agency for Research on Cancer, LyonGoogle Scholar
  12. IARC, 1986, “Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 38, Tobacco smoking”, International Agency for Research on Cancer, LyonGoogle Scholar
  13. IARC, 1988, “Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement No 7, Overall evaluations of carcinogenicity: An update of IARC Monographs Volumes 1–42”, International Agency for Research on Cancer, Lyon.Google Scholar
  14. Jick, H., Watkins, R. N., Hunter, J. R., Dinan, B. J., Madsen, S., Rothman, K. J., and Walker, A. M., 1979, Replacement estrogens and endometrial cancer. New Engl. J. Med., 300: 218.PubMedCrossRefGoogle Scholar
  15. Kaldor, J. M., Day, N. E., and Hemminki, K., 1988, Quantifying the carcinogenicity of antineoplastic drugs. Eur. J. Cancer Clin. Oncol., 24: 703.PubMedCrossRefGoogle Scholar
  16. Kinlen, L. J., Sheil, A. G. R., Peto, J., and Doll, R., 1979, Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br. Med. J., 2: 1461.PubMedCrossRefGoogle Scholar
  17. Kohn, K. W., Hartley, J. A., and Mattes, W. B., 1987, Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucl. Acids Res., 15: 10531.PubMedCrossRefGoogle Scholar
  18. Margison, G. P., and O’Connor, P. J., 1979, Nucleic acid modification by N-nitroso compounds, in: “Chemical carcinogens and DNA, Vol. I”, P. L. Grover, ed., CRC Press, Boca Raton, FloridaGoogle Scholar
  19. Pedersen-Bjergaard, J., Nissen, N. I., Sorensen, H. M., Hou-Jensen, K., Larson, M. S., Ernst, P., Ersbml, J., Knudtzon, S., and Rose, C., 1982, Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (dihydroxybusulfan). Cancer, 45: 19.CrossRefGoogle Scholar
  20. Penn, I., 1987, Malignancies induced by drugs therapy: a review, in: Carcinogenicity of alkylating cytostatic drugs, (IARC Scientific Publications No 78), D. Schmähl, and J. M. Kaldor, eds., International Agency for Research on Cancer, Lyon.Google Scholar
  21. Peto, J., 1979, Dose response relationships for asbestos related disease: Implications for hygiene standards. II. Mortality. Ann. NY Acad. Sci., 330: 195CrossRefGoogle Scholar
  22. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N., 1984, The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic exposure animal experiments. Environ. Health Perspect., 58: 1.PubMedGoogle Scholar
  23. Stott, H., Fox, W., Girling, D. J., Stephens, R.J., and Galton, D. A. G, 1977, Acute leukaemia after busulphan. Br. med. J., 2: 1513.PubMedCrossRefGoogle Scholar
  24. Tucker, M. A., Coleman, C. N., Cox, R.S., Varghese, A., Rosenberg, S. A., 1987, Risk of second cancers after treatment for Hodgkin’s disease. New Engl. J. Med., 318: 76.CrossRefGoogle Scholar
  25. Tuyns, A.J., Pequignot, G., Jensen, O.M., 1977, Le cancer de l’esophage en Ille-et-Vilaine en fonction des niveaux de consommation d’alcool et de tabac. Bull. Cancer, 64: 45.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • J. M. Kaldor
    • 1
  • D. E. G. Shuker
    • 1
  1. 1.International Agency for Research on CancerLyonFrance

Personalised recommendations